scholarly journals OBESITY AND ITS RELATIONSHIP WITH CANCER: PART IV

2021 ◽  
pp. 37-48
Keyword(s):  
Multiple Myeloma ◽  
Gall Bladder ◽  
General Relationship ◽  
Specific Impact

Part I thru III discussed obesity, its general relationship with cancer and its specific impact on six cancers, namely those involving the breast, colorectal tissues, esophagus, stomach. gall bladder, and liver. This part (Part IV) deals with obesity and its relationship with cancers of the endometrium, ovary, pancreas, prostate, kidneys, thyroid, and lung. Meningioma and multiple myeloma are also discussed.

Gastric and gall bladder carcinoma in a patient with multiple myeloma.

1987 ◽  
Vol 76 (12) ◽  
pp. 1847-1850
Author(s):  
Shigeo AOKI ◽  
Hiroki KIRIYAMA ◽  
Kenji HAI ◽  
Kenshu UEHARA ◽  
Hitoshi TERAOKA ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Gall Bladder ◽  
Bladder Carcinoma ◽  
Gall Bladder Carcinoma

scholarly journals CANCER TYPES;

2018 ◽  
Vol 21 (01) ◽  
pp. 116-122
Author(s):  
Abdul Matin Qaisar ◽  
Ghazanfar Ali Sirhindi ◽  
Shamayal Mandokhel
Keyword(s):  
Lung Cancer ◽  
Ovarian Cancer ◽  
Multiple Myeloma ◽  
Liver Cancer ◽  
Liver Function ◽  
Gall Bladder ◽  
Hodgkin Lymphoma ◽  
Liver Function Tests ◽  
Industrial Workers ◽  
Function Tests

Introduction: This study attempts to highlight the relation of various types ofcancers to abnormalities in liver and renal function tests. Objectives: Correlation of derangedrenal and liver function tests to different types of cancers in industrial workers who are exposed toindustrial chemicals and carcinogens. Patients and Methods: This non-interventional studyincluded 100 hundred confirmed cases of cancer were selected and studied from July 2011 toDecember 2011. The study was conducted at Fatima Memorial Hospital/College of Medicine &Dentistry, Lahore . Results: Out of these 100 patients, 21 had CA lung, 19 had lymphoma, 14 hadsarcoma, 13 had CA breast, 6 had CA prostate, 4 had CA liver, 3 had CA colon, 3 had CA ovary, 3had CA testis, 2 had leukemia, 2 had multiple myeloma, 2 had CA gall bladder, 2 had CA stomach,1 had CA esophagus, 1had CA tongue, 1had CA parotid, 1 had CA rectum, 1 had CA cervix and 1had CA larynx. Among lymphoma, non-Hodgkin lymphoma was more than Hodgkin lymphoma(out of 19 patients, 13 had non-Hodgkin and 6 had Hodgkin lymphoma). Out of 14 patients ofsarcomas, 5 had Ewing sarcoma, 4 had chondrosarcoma, 3 had fibrosarcoma and 2 hadliposarcoma. Similarly the serum bilirubin levels in liver cancer, ovarian cancer, multiplemyeloma, stomach and gall bladder cancer were 1.50±0.31, 1.17±0.10, 1.46±0.15 and1.40±0.50 mg% were 32.38±18.81, 37.73±4.35, 34.43±4.35, 45.00±46.17, 31.33±44.70,65.25±31.14, 33.67±80.90, 99.00±73.08, 50.00±98.49, 33.50±75.0, 36.50±85.0 and49.0±11.0 μ/l respectively which were statistically significantly higher (p<0.05) then controlindividuals. respectively which were significantly higher (p<0.05) than the control individualsSimilarly the ALT levels in lung cancer, lymphoma, sarcoma, breast cancer , prostate cancer, livercancer, leukemia, ovarian cancer, cancer of colon, multiple myeloma, cancer of testis andstomach. The mean serum creatinine levels in lung cancer, liver cancer and cancer of colon were0.89±0.05, 0.90±0.16 mg% respectively which were significantly higher than the controlindividuals (p<0.05). Conclusions: The renal and liver function tests should be frequentlymonitored in cancer patients from industrial back grounds.

scholarly journals OBESITY AND ITS RELATIONSHIP WITH CANCER: PART III

2021 ◽  
pp. 25-36
Keyword(s):  
Multiple Myeloma ◽  
Gall Bladder ◽  
Lung Carcinomas ◽  
Obesity And Cancer

Obesity and cancer has been discussed in the first two parts. This part (Part III) deals with six cancers, namely those involving the breast, colorectal tissues, esophagus, stomach. gall bladder, and liver. Their relationship with obesity is discussed. Part IV will look at endometrial, ovarian, pancreatic, prostate, renal, thyroid and lung carcinomas. Meningioma and multiple myeloma are also discussed.

Proteasome inhibitors as therapeutics

2005 ◽  
Vol 41 ◽  
pp. 205-218
Author(s):  
Constantine S. Mitsiades ◽  
Nicholas Mitsiades ◽  
Teru Hideshima ◽  
Paul G. Richardson ◽  
Kenneth C. Anderson
Keyword(s):  
Multiple Myeloma ◽  
Drug Class ◽  
Proteasome Inhibitors ◽  
Cell Cycle Regulators ◽  
Current State ◽  
Intracellular Mechanism ◽  
Ubiquitin Proteasome ◽  
Proteasome Pathway ◽  
Hodgkin's Lymphomas ◽  
Clinical Research Data

The ubiquitin–proteasome pathway is a principle intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies, because of the pleiotropic cell-cycle regulators and modulators of apoptosis that are controlled by proteasome function. In this chapter, we review the current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the U.S. Food and Drug Administration for the treatment of advanced multiple myeloma. Particular emphasis is placed on the pre-clinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and a appraisal of possible uses in other haematological malignancies, such non-Hodgkin's lymphomas.

Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients

2000 ◽  
Vol 111 (4) ◽  
pp. 1118-1121 ◽  
Author(s):  
A. Bellahcene ◽  
I. Van Riet ◽  
C. de Greef ◽  
N. Antoine ◽  
M. F. Young ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Protein Expression ◽  
Cell Lines ◽  
Myeloma Cell ◽  
Bone Sialoprotein ◽  
Multiple Myeloma Cell ◽  
Human Multiple Myeloma ◽  
Mrna And Protein Expression

Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma

2000 ◽  
Vol 111 (1) ◽  
pp. 381-381 ◽  
Author(s):  
C. W. Tiplady ◽  
G. P. Summerfield
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Refractory Multiple Myeloma

Controversies surrounding the clonogenic origin of multiple myeloma

2000 ◽  
Vol 110 (1) ◽  
pp. 240-241 ◽  
Author(s):  
Faith E. Davies ◽  
Andrew C. Rawstron ◽  
Roger G. Owen ◽  
Gareth J. Morgan
Keyword(s):  
Multiple Myeloma

Sturge-Weber syndrome and multiple myeloma

1969 ◽  
Vol 100 (4) ◽  
pp. 488b-488
Author(s):  
H. O. Curth
Keyword(s):  
Multiple Myeloma ◽  
Weber Syndrome ◽  
Sturge Weber Syndrome
Sign in / Sign up

Export Citation Format

Share Document